MOTS-c is a mitochondrial peptide involved in how cells respond when energy is limited. It is claimed to improve energy, endurance, metabolism and healthy aging.
What MOTS-c does and why that matters
MOTS-c is a peptide made from mitochondrial DNA and is involved in how cells respond when energy is limited. In mice, administered MOTS-c changed glucose use and improved physical performance. It is claimed to improve energy, exercise endurance, weight control and healthy aging. The human research cited here measured the body's own MOTS-c response to exercise; it did not show that MOTS-c injections improve those outcomes in people. [1,2,3]
Function evidence: Cell and mouse metabolism findings; injected human benefit unproven
What people hope to notice
The usual expectations are more day-to-day energy, better endurance during exercise, easier weight control or less decline with age. Administered MOTS-c changed metabolism and physical performance in mice. The human part of the exercise research observed the body's own MOTS-c response; it did not give people MOTS-c and test whether they could walk, run or train for longer. A naturally occurring peptide changing during exercise does not show that an injected version recreates exercise or produces a noticeable benefit. [1,2,3]
What supports this description: Mouse treatment studies and human observation; injected human outcomes untested
MOTS-c Dosing status
Dose: No established routine treatment dose in the cited evidence. | Frequency: No validated routine schedule. | Cycle: No validated cycling schedule. | Route: Research routes do not establish a routine treatment route.
Preparation: No validated patient preparation instructions in these sources..
The cited studies do not establish a human treatment, preparation or storage protocol. FDA's assessment reports no identified human exposure data for drug products containing MOTS-c. [1,2,3]
MOTS-c Effects
Metabolic findings. MOTS-c affected AMPK-related pathways in experimental systems and improved insulin sensitivity in mouse models. Human treatment benefit cannot be inferred from those results. [1]
Exercise research. The 2021 study combined mouse treatment experiments with human exercise observations. It did not test whether injecting MOTS-c improves human endurance. [2]
MOTS-c Side Effects
Safety remains uncertain. FDA identifies potential immune-response and impurity risks, and reports no identified human exposure data for drug products containing MOTS-c. Reliable human adverse-event rates are not established by these sources. [3]
Frequently Asked Questions About MOTS-c
Is MOTS-c naturally produced?
The discovery study identified a mitochondrial DNA sequence encoding the peptide. A naturally occurring molecule still needs human safety and efficacy evidence before an administered product can be treated as a validated therapy. [1,3]
Does MOTS-c improve endurance in people?
The cited exercise study found treatment effects in mice and measured naturally produced MOTS-c during exercise in humans. It does not establish a benefit from human injections. [2]
Is there an established dose or cycle?
These sources do not establish a routine human dose, treatment duration or cycling schedule. Animal dosing cannot supply a validated patient regimen. [1,2,3]
Is early fatigue evidence that treatment is working?
These sources do not establish an adjustment phase or a timeline in which fatigue predicts later benefit. [1,2,3]
Evidence
Preclinical treatment evidence. Treatment experiments reported metabolic and physical-performance effects in mice. Human exercise observations measured endogenous MOTS-c, not a treatment benefit from injections. [1,2]
Approval status: No established clinical treatment in the cited sources. [1,2,3]
References
Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. PMID 25738459
Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021. PMID 33473109
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks , 2026. Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
